Retroviral pseudotransduction for targeted cell manipulation

被引:60
作者
Galla, M
Will, E
Kraunus, J
Chen, L
Baum, C [1 ]
机构
[1] Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA
[2] Hannover Med Sch, Dept Hematol Hemostaseol & Oncol, D-3000 Hannover, Germany
关键词
D O I
10.1016/j.molcel.2004.09.023
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The present study addressed whether retroviral vectors could be modified to achieve receptor-mediated, dose-controlled, and transient delivery of proteins or nucleic acids into targeted cells. As a paradigm, we generated mouse leukemia virus-based vectors encoding the site-specific recombinase Cre. The vectors were disabled in primer binding site function, blocking reverse transcription of the virion mRNA. While reducing transgene insertion more than 1000-fold and abolishing toxic effects of constitutive Cre expression, transient Cre delivery was still highly efficient, receptor restricted, and insensitive to pharmacologic inhibition of reverse transcription. This form of Cre transfer required the retroviral packaging signal, cap-proximal positioning of the translation unit, as well as gag and env expression in producer cells, revealing retroviral mRNA transfer as the underlying mechanism. Thus, retrovirally delivered mRNA may serve as an immediate translation template if not being reverse transcribed. This approach allows multiple modifications for targeted and reversible cell manipulation with nucleic acids.
引用
收藏
页码:309 / 315
页数:7
相关论文
共 29 条
[1]   MOLONEY MURINE LEUKEMIA-VIRUS INTEGRATION PROTEIN PRODUCED IN YEAST BINDS SPECIFICALLY TO VIRAL ATT SITES [J].
BASU, S ;
VARMUS, HE .
JOURNAL OF VIROLOGY, 1990, 64 (11) :5617-5625
[2]   Characterization of murine leukemia virus restriction in mammals [J].
Besnier, C ;
Ylinen, L ;
Strange, B ;
Lister, A ;
Takeuchi, Y ;
Goff, SP ;
Towers, GJ .
JOURNAL OF VIROLOGY, 2003, 77 (24) :13403-13406
[3]   Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: Generation, concentration, and broad host range [J].
Beyer, WR ;
Westphal, M ;
Ostertag, W ;
von Laer, D .
JOURNAL OF VIROLOGY, 2002, 76 (03) :1488-1495
[4]   Packaging cell line DNA contamination of vector supernatants: Implication for laboratory and clinical research [J].
Chen, J ;
Reeves, L ;
Sanburn, N ;
Croop, J ;
Williams, DA ;
Cornetta, K .
VIROLOGY, 2001, 282 (01) :186-197
[5]   Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors [J].
Chowdhury, S ;
Chester, KA ;
Bridgewater, J ;
Collins, MK ;
Martin, F .
MOLECULAR THERAPY, 2004, 9 (01) :85-92
[6]   HIGH-TITER PACKAGING CELLS PRODUCING RECOMBINANT RETROVIRUSES RESISTANT TO HUMAN SERUM [J].
COSSET, FL ;
TAKEUCHI, Y ;
BATTINI, JL ;
WEISS, RA ;
COLLINS, MKL .
JOURNAL OF VIROLOGY, 1995, 69 (12) :7430-7436
[7]   Cre-loxP biochemistry [J].
Ghosh, K ;
Van Duyne, GD .
METHODS, 2002, 28 (03) :374-383
[8]   POINT MUTANTS OF MOLONEY MURINE LEUKEMIA-VIRUS THAT FAIL TO PACKAGE VIRAL-RNA - EVIDENCE FOR SPECIFIC RNA RECOGNITION BY A ZINC FINGER-LIKE PROTEIN-SEQUENCE [J].
GORELICK, RJ ;
HENDERSON, LE ;
HANSER, JP ;
REIN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (22) :8420-8424
[9]   Site-specific gene targeting for gene expression in eukaryotes [J].
Gorman, C ;
Bullock, C .
CURRENT OPINION IN BIOTECHNOLOGY, 2000, 11 (05) :455-460
[10]   Critical factors influencing stable transduction of human CD34+ cells with HIV-1-derived lentiviral vectors [J].
Haas, DL ;
Case, SS ;
Crooks, GM ;
Kohn, DB .
MOLECULAR THERAPY, 2000, 2 (01) :71-80